Showing 1491-1500 of 1692 results for "".
- Faster—and Free—Genetic Testing for Spinal Muscular Atrophyhttps://practicalneurology.com/news/fasterand-freegenetic-testing-for-spinal-muscular-atrophy/2468996/A new genetic test for spinal muscular atrophy (SMA) provides results in 4 days vs the 21 day wait previously needed. Early diagnosis is essential for early treatment, shown to slow disease progression, prolong survival by years, and improve or stabilize loss of motor function. Of note, the test
- Fosgonimeton Well Tolerated With Possible Benefits for Alzheimer Disease in the Absence of Cholinergic Treatmenthttps://practicalneurology.com/news/fosgonimeton-well-tolerated-with-possible-benefits-for-alzheimer-disease-in-the-absence-of-cholinergic-treatment/2469991/In the phase 2 ACT-AD trial (NCT04491006), fosgonimeton (Athira Pharma, Bothell, WA) was well-tolerated, and no serious adverse events (AEs ) occurred. Mild-to-moderate AEs occurred in 89% (24/27) and 100% (26/26), respectively,
- 2024 Brain Health Academy Launches with Free Online Courses/Credits For Health Care Providers About Dementia Risk Reduction Tacticshttps://practicalneurology.com/news/2024-brain-health-academy-launches-with-free-online-coursescredits-for-healthcare-providers-about-dementia-risk-reduction-tactics/2470461/The 2024 Brain Health Academy, a series of educational courses provided by the nonprofit organization UsAgainstAlzheimer’s, will begin on Thursday, May 9, 2024. The online courses are free of charge and are intended to provide health care and wellness providers with tools and resources to a
- Vigabatrin Recall Issued for One Lot of Seizure Medicationhttps://practicalneurology.com/news/vigabatrin-recall-issued-for-one-lot-of-seizure-medication-2/2470366/One particular lot of vigabatrin for oral solution US pharmacopeia (USP) 500 mg designated NB301030 has been recalled by InvaGen Pharmaceuticals (Hauppauge, NY)), a subsidiary of Cipla USA (Warren, NJ). Vigabatrin is indicated to treat refractory complex partial seizures as an adjunctive therapy
- Immuno-Infrared Sensor is Able to Identify Symptom-Free Alzheimer Diseasehttps://practicalneurology.com/news/immuno-infrared-sensor-is-able-to-identify-symptom-free-alzheimer-disease/2469972/Alzheimer disease (AD) is thought to begin 15 to 20 years before clinical symptoms are seen, making early identification of presymptomatic disease a priority. As published in the journal Alzheimer’s & Dementia, new results compared sensitivity of an immune-infrared sensor with the compl
- Phase 2 Glioblastoma Multiforme Study Exhibits Progression Free Survivalhttps://practicalneurology.com/news/inovio-exhibits-progression-free-survival-in-phase-2-glioblastoma-multiforme-study/2469068/Positive interm results of a T cell-activating immunotherapy (INO-5401; Inovio Pharmaceuticals, Plymouth Meeting, PA) were seen in a phase 2 study (NCT03491683) of a T cell-activating immunotherapy for treatment of newly diagnosed gliob
- Eptinezumab Treatment Provides Prolonged Periods of Migraine-Free Monthshttps://practicalneurology.com/news/eptinezumab-treatment-provides-prolonged-periods-of-migraine-free-months/2468954/Treatment with eptinezumab (Alder BioPharmaceuticals, Bothell, WA) in the PROMISE-1 and PROMISE-2 clinical trials (NCT02559895, NCT02974153) resulted in 1 or more months fre
- Physician Visits Increased Up to 15 Years Before MS Symptom Onsethttps://practicalneurology.com/news/physician-visits-increased-up-to-15-years-before-ms-symptom-onset/2476101/Results from a large, matched cohort study published in JAMA Network Open reveal that health care use begins to rise 14 to 15 years before the onset of the first recognized symptoms of multiple sclerosis (MS). The findings suggest a longer prodromal phase than previously understood, with
- Prescription Digital Therapeutic Reduced Insomnia Severity and Decreased Emergency Department Visitshttps://practicalneurology.com/news/prescription-digital-therapeutic-reduced-insomnia-severity-and-decreased-emergency-department-visits/2470000/In analysis of real-world data, prescription digital therapeutic (PDT) (Somryst; Pear Therapeutics, Boston, MA) showed clinically meaningful reductions in insomnia severity index (ISI) score after 9 weeks of. People who used the PDT also had reductions in health-related services and costs in the
- Study Suggests Key Topics to Discuss in Initial Alzheimer’s Diagnostic Visithttps://practicalneurology.com/news/study-suggests-key-topics-to-discuss-in-initial-alzheimers-diagnostic-visit/2468963/Research has identified 17 topics in 4 categories that people with Alzheimer’s disease (AD), their caregivers, and health care professionals feel are important to discuss, as well as the timing for the discussion topics (Table).